Trial Profile
A Phase I Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Dabrafenib; Trametinib
- Indications Malignant melanoma
- Focus Adverse reactions
- 10 Dec 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 09 Feb 2015 New trial record